Lifeboat Foundation

A new technology is allowing one company to produce full-spectrum cannabis without growing the plant itself.

Sounds like something out of a science fiction movie, but it’s very real. In what could be a global first, this week, a publicly traded Canadian-Israeli biotech firm company, BioHarvest Sciences, will announce that it has managed to produce at least 10kg of full-spectrum cannabis without the plant itself.

According to information procured exclusively, the biomass in question was created using the company’s proprietary BioFarming technology platform, which allows it to grow natural plant cells in bioreactors. In addition, management assures, the product is not genetically modified, and is “uniquely consistent and clean.” This could provide an interesting solution to two of the cannabis industry’s main pain points: product variability and contamination — the aseptic, controlled environment means the product isn’t affected by fungi, yeast, mold or any other contaminants or pesticides.

Continue reading “Producing Cannabis Biomass Without Growing A Cannabis Plant: How One Company Is Doing It” »

The double-helix structure has practically become synonymous with DNA, but it isn’t the only way long strands of genetic information squeeze themselves into a tight space.

When a double-strand of DNA doubles back on itself or attaches to another double-strand, it can actually create a quadruple-stranded knot, known as a G-quadruplex.

Scientists first discovered these ‘double-double-helixes’ in living human cells in 2013, and in the years since, these knots have been found in high concentrations in cancerous cells.

Researchers from the Skolkovo Institute of Science and Technology and Saratov State University have come up with an inexpensive method for visualizing blood flow in the brain. The new technique is so precise it discerns the motions of individual red blood cells — all without the use of toxic dyeing agents or expensive genetic engineering. The study was published in The European Physical Journal Plus.

To understand more about how the brain’s blood supply works, researchers map its blood vessel networks. The resulting visualizations can rely on a variety of methods. One highly precise technique involves injecting fluorescent dyes into the blood flow and detecting the infrared light they emit. The problem with dyes is they are toxic and also may distort mapping results by affecting the vessels. Alternatively, researchers employ genetically modified animals, whose interior lining of blood vessels is engineered to give off light with no foreign substances involved. Both methods are very expensive, though.

Researchers from Skoltech and Saratov State University have devised an inexpensive method for visualizing even the smallest capillaries in the brain. The method — which integrates optical microscopy and image processing — is dye-free and very fine-grained, owing to its ability to detect each and every red blood cell travelling along a blood vessel. Since the number of RBCs in capillaries is not that high, every cell counts, so this is an important advantage over other methods, including dye-free ones.

As we age, our muscles gradually become smaller, weaker and less able to heal after injury. In a new study, UPMC and University of Pittsburgh researchers pinpoint an important mediator of youthfulness in mouse muscle, a discovery that could advance muscle regeneration therapies for older people.

Published today in Nature Aging, the study demonstrates that circulating shuttles called extracellular vesicles, or EVs, deliver genetic instructions for the longevity protein known as Klotho to muscle cells. Loss of muscle function and impaired muscle repair in old mice may be driven by aged EVs, which carry fewer copies of these instructions than those in young animals.

The findings are an important advance in understanding why the capacity for muscles to regenerate dwindles with age.

http://spie.org/bios.

Boyden’s award-winning research has led to tools that can activate or silence neurons with light, enabling the causal assessment of how specific neurons contribute to normal and pathological brain functions.

Continue reading “Ed Boyden on Optogenetics —- selective brain stimulation with light” »

Nick talks to Stanford psychiatrist and neuroscientist Dr. Karl Deisseroth. They discuss a range of topics about the brain, including autism, depression, bipolar disorder, dissociation, and more. They also talk about optogenetics, a technique Karl co-developed which uses light to control specific neurons in the brain, allowing neuroscientists to turn circuits in the brain on and off to reveal how the brain generates perception, emotion, and behavior. They also talk about Karls’ new book, “Projections: A Story of Human Emotion.”

Buy “Projections” by Karl Deisseroth: https://www.amazon.com/gp/product/1984853694/ref=as_li_tl?ie…40e9fc7537
Support the podcast: https://www.patreon.com/nickjikomes.
Organize your e-book highlights & notes w/ the Readwise app (two months free with signup through link): readwise.io/nickjikomes.
Start your own podcast ($20 Amazon gift card after signup): https://www.buzzsprout.com/?referrer_…
Learn more about this episode’s sponsor, Dosist: https://dosist.com/

Continue reading “Karl Deisseroth: Optogenetics, Psychiatry, Emotion, Autism, Dissociation & ‘Projections’ | #35” »

Associate Professor of Biological Engineering and Brain and Cognitive Sciences Ed Boyden explains optogenetics and how it is used in neurological research.

Video: Emily Heusted

In this episode, I talk to world-renowned biologist David Sinclair about aging and longevity. David rejects the notion that the deterioration of health is a natural part of growing old and asserts that aging is a disease itself that we need to reverse. But how will a reset of our biological clocks affect our interactions, responses to adversity, morality, and how we live our lives? We discuss the ethical implications of limitless lifespans and also touch on the topics of death, evolution, genetics, medicine, and data tracking.

Bio.
Dr. David Sinclair is a professor in the department of genetics and co-director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School and co-founder of the scientific journal Aging. He is best known for his work on understanding why we age and how to slow its effects. In addition to being a co-founder of several biotechnology companies, he’s the author of the book Lifespan: Why We Age – and Why We Don’t Have To. Dr. Sinclair was listed by TIME magazine as one of the “100 most influential people in the world”.

Continue reading “David Sinclair || Why We Age and Why We Don’t Have To” »

Circa 2019

Researchers of Sechenov University and University of Pittsburgh described the most promising strategies in applying genetic engineering for studying and treating Parkinson’s disease. This method can help evaluate the role of various cellular processes in pathology progression, develop new drugs and therapies, and estimate their efficacy using animal disease models. The study was published in Free Radical Biology and Medicine.

Parkinson’s disease is a neurodegenerative disorder accompanied by a wide array of motor and cognitive impairments. It develops mostly among elderly people (after the age of 55–60). Parkinson’s symptoms usually begin gradually and get worse over time. As the disease progresses, people may have difficulty controlling their movements, walking and talking and, more importantly, taking care of themselves. Although there is no cure for Parkinson’s disease, medicines, surgical treatment, and other therapies can often relieve some symptoms.

Continue reading “Scientists listed ways of applying genetic engineering to treat Parkinson’s disease” »